walk a tightrope between bleeding and clot-ting—and a hundred things can tip the balance. It’s a difficult drug to use, with a narrow therapeu-tic index, but 60 years after it was introduced it is still the mainstay of oral anticoagulant treatment. More than 2 million North Americans take it, and this number continues to grow with our aging pop-ulation.1 Only a minority of these patients are man-aged by anticoagulation clinics, despite evi-dence that patients managed by anticoagula-tion clinics have fewer bleeding and throm-boembolic events than those who receive usual medical care,2,3 and their international normalized ratios (INRs) are in the therapeu-tic range a greater percentage of the time.4–7 Therefore, everyone who prescribes war-fa...
Substantial inter-patient variability exists in the anti-thrombotic response to warfarin. This state...
For over 60 years, despite many inher-ent problems with their use, heparin and vitamin K antagonists...
Clinicians should be aware of new developments to familiarize themselves with pharmacokinetic and ph...
walk a tightrope between bleeding and clot-ting—and a hundred things can tip the balance. It’s a dif...
Warfarin has been in clinical use for nearly 60 years, andin 2010 there were 25 million prescription...
Oral anticoagulants are the most commonly used agents in the long term prophylaxis and treatment of ...
Warfarin is very effective in preventing thrombo-embolic events, but it is probably one of the most ...
Coumarins were discovered in the late 1930s as a result of decades of research spent identifying th...
Oral anticoagulant (OAC) therapy is currently gaining special importance due to the significant spre...
Warfarin is the single most effective treatment to preventstroke in patients with atrial fibrillatio...
Background: Anticoagulation control is a strong predictor of Iclinical outcomes for patients on warf...
<p><strong>Aim.</strong> To study the structure and incidence of the in-hospital anticoagulants pres...
Valvular heart diseases affect millions of patients worldwide, and the burden is rising as the popul...
Maintaining a patient within a therapeutic international normalized ratio (INR) is the main aim of t...
et al. This is an open-access article distributed under the terms of the Creative Commons Attributio...
Substantial inter-patient variability exists in the anti-thrombotic response to warfarin. This state...
For over 60 years, despite many inher-ent problems with their use, heparin and vitamin K antagonists...
Clinicians should be aware of new developments to familiarize themselves with pharmacokinetic and ph...
walk a tightrope between bleeding and clot-ting—and a hundred things can tip the balance. It’s a dif...
Warfarin has been in clinical use for nearly 60 years, andin 2010 there were 25 million prescription...
Oral anticoagulants are the most commonly used agents in the long term prophylaxis and treatment of ...
Warfarin is very effective in preventing thrombo-embolic events, but it is probably one of the most ...
Coumarins were discovered in the late 1930s as a result of decades of research spent identifying th...
Oral anticoagulant (OAC) therapy is currently gaining special importance due to the significant spre...
Warfarin is the single most effective treatment to preventstroke in patients with atrial fibrillatio...
Background: Anticoagulation control is a strong predictor of Iclinical outcomes for patients on warf...
<p><strong>Aim.</strong> To study the structure and incidence of the in-hospital anticoagulants pres...
Valvular heart diseases affect millions of patients worldwide, and the burden is rising as the popul...
Maintaining a patient within a therapeutic international normalized ratio (INR) is the main aim of t...
et al. This is an open-access article distributed under the terms of the Creative Commons Attributio...
Substantial inter-patient variability exists in the anti-thrombotic response to warfarin. This state...
For over 60 years, despite many inher-ent problems with their use, heparin and vitamin K antagonists...
Clinicians should be aware of new developments to familiarize themselves with pharmacokinetic and ph...